Matt Phipps

“Nice to take my question, Chris, and a good quarter. With both the Opdivo and Keytruda BLAs filed, I'm just curious what your assumptions are around being able to – when you can commercially launch those, and how do you think about penetrating the market that is kind of being moved to subcutaneous formulation?”

“Nice to take my question, Chris, and a good quarter. With both the Opdivo and Keytruda BLAs filed, I'm just curious what your assumptions are around being able to – when you can commercially launch those, and how do you think about penetrating the market that is kind of being moved to subcutaneous formulation?”

“Last quarter, there was a lot of talk about ready and wait patients versus organic demand. So just wondering if this 7,000 patients you feel really fits into that organic demand category you described previously and if that should be the assumption for the rest of the year.”

“Pablo, you mentioned the totality of the data did not support continue to develop 058 for the V617F indication. Over the past year, it seems like the issue has really been around the bioavailability of this drug and being able to achieve target coverage.”

“Adam, I was wondering if you could help us on if the upfront payment from CERB will be recognized on the P&L in the third quarter.”